Vision Source Kingsford Optometrist Medicare: Medicare Enrolled Practice Location: 401 Woodward Ave, Kingsford, MI 49802 Phone: 906-774-0611 Fax: 906-774-2796 |
Dr. Nelson Howard Hassell, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 401 Woodward Ave, Kingsford, MI 49802 Phone: 906-774-0611 Fax: 906-774-2796 |
News Archive
There is, therefore, a great need to understand how the illness can be diagnosed using more convenient and inexpensive methods. A new study posted to the medRxiv preprint server reveals the potential role of skin imprints to test for biomarkers that indicate a diagnosis of COVID-19 in a non-invasive way.
The most common reasons that clinicians give to explain medically futile treatment at the end of life are emotional difficulties, such as a fear of talking about death, and institutional barriers, such as hospital departments expecting them to "do everything possible," report German researchers.
Couples considering undergoing assisted reproductive technology (ART) treatment should be informed about the increased risk of congenital malformation posed by the use of ART, the annual conference of the European Society of Human Genetics will hear today (Monday). Dr. G-raldine Viot, a clinical geneticist at the Maternit- Port Royal hospital, Paris, France, will say that she believed that most doctors working in ART clinics in France only told couples about such risks if they were asked specific questions.
BGI, the world's largest genomics organization, based in China, and The Vancouver Prostate Centre, a global leader in translational research in cancer, today announced the establishment of the BGI-VPC Joint Research Laboratory, a sequencing and translational research facility, to jointly discover and advance basic and translational programs in oncology, including personalized oncology.
Northwest Biotherapeutics today announced that it has accelerated the addition of clinical trial sites, exceeding its projections for the doubling of such sites across the U.S. this calendar quarter, for enrollment of new patients into the Company's ongoing 240-patient randomized, double blind, placebo controlled clinical trial of DCVax immune therapy for Glioblastoma multiforme, the most lethal form of brain cancer.
› Verified 2 days ago